Iron chelation with deferasirox in two patients with HFE hemochromatosis and chronic anemia
Related Experiment Video
Updated: Jun 1, 2026

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
Published on: February 23, 2024
Michael Nagler1, M Gregor, W A Wuillemin
1Division of Hematology and Central Hematology Laboratory, Luzerner Kantonsspital, Lucerne, Switzerland. michael.nagler@ksl.ch
We present 2 patients with hyperferritinemia, increased liver iron and hemochromatosis-associated HFE genotypes. At diagnosis, both patients had chronic anemia that prevented initiation of phlebotomy. Iron chelation with deferasirox proved to be a safe and effective means of substantially lowering ferritin levels.
We present 2 patients with hyperferritinemia, increased liver iron and hemochromatosis-associated HFE genotypes. At diagnosis, both patients had chronic anemia that prevented initiation of phlebotomy. Iron chelation with deferasirox proved to be a safe and effective means of substantially lowering ferritin levels.
More Related Videos
Related Concept Videos
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
The Early Endosome: Endocytosis of Transferrin
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Lifecycle of Erythrocytes
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups.
The Periodic Table and Organismal Elements

